Blog

Wednesday, 17 June 2020 10:38

We’re analysing new COVID-19 drug- WHO

Rate this item
(0 votes)

wereThe World Health Organisation (WHO) has described the initial clinical trial results from the United Kingdom (UK) that shows dexamethasone can be lifesaving for treating patients critically ill with COVID-19 as a welcome development.

It however said an in-depth analysis of the intervention will be carried out before issuing clinical guidance on how and when the drug should be used.
The WHO Director-General, Dr. Tedros Adhanom Ghebreyesus, made this known on Wednesday in a statement.

According to him: “This is a welcome news. I congratulate the Government of the United Kingdom, University of Oxford, the research groups, hospitals, patients and families who have collectively contributed to this lifesaving breakthrough.

“WHO looks forward to learning more about the dexamethasone study. This is the first treatment to be shown to reduce mortality in severely ill patients with COVID-19 requiring oxygen or ventilator support.

“There are many ongoing clinical trials for COVID-19, including the Solidarity Trial launched by WHO and partners. It is hoped that more treatments under clinical evaluation will result in improving patient outcomes and save lives.

“While we are searching for COVID-19 treatments, we must continue strong efforts to prevent as many infections as possible by finding, isolating, testing and caring for every case; and tracing and quarantining every contact.”

source: TheNation

 

 
Read 264 times Last modified on Monday, 26 July 2021 08:28

Mission and Vision

Our Mission: Advocacy, capacity building, improving access to finance for the private sector in collaboration with the public sector      

Our Vision: To support the achievement of universal healthcare coverage through private sector activation.

Get In Touch

Contact Us:
● Email: info@hfnigeria.com
● Call: +234 703 056 7554
● Address: 3rd floor, 109, Awolowo Road, Opposite Standard Chartered Bank, Ikoyi, Lagos
State, Nigeria